How much weight do people regain after stopping semaglutide?

In the STEP 1 extension, participants regained about two-thirds of their prior semaglutide-associated weight loss during the year after treatment ended. The group had lost 17.3% on average and regained 11.6 percentage points, leaving a 5.6% mean net loss from baseline. Those are trial averages, not a prediction of what any one person will regain.

Will I regain all the weight after stopping semaglutide?

Not necessarily. In STEP 1, the average participant retained some net weight loss one year after withdrawal, but the amount varied. Appetite, duration of treatment, starting weight, medical conditions, follow-up support and individual biology can all affect the trajectory. The evidence supports planning for possible regain, not assuming that complete regain is inevitable.

Can semaglutide be stopped without tapering?

There is no universal, trial-proven taper protocol. Major withdrawal trials either ended treatment or switched participants to placebo; they did not compare abrupt stopping with a gradual reduction. A prescriber may consider tapering to observe appetite, glucose, side effects or weight response, but the decision and schedule depend on the reason for treatment and the patient's clinical circumstances.

How long do semaglutide's effects last after the final dose?

They fade gradually over several weeks. Semaglutide's half-life is approximately one week, so a small fraction remains after about five weeks. Appetite or digestive effects may change before the medication is fully cleared, and the timing varies by person. The return of hunger is a loss of medication effect, not a classic drug-withdrawal syndrome.

Does stopping semaglutide reverse its health effects?

Some improvements may move back toward baseline. In the STEP 1 extension, most measured cardiometabolic changes—including blood pressure and lipid measures—trended toward baseline during the year after withdrawal. That does not mean every benefit disappears or every person follows the average. Monitoring should reflect the original treatment goal, especially when diabetes or cardiovascular risk is involved.

What Happens When You Stop Taking Semaglutide

What happens when you stop taking semaglutide is usually gradual, not a sudden withdrawal reaction. As the medication clears over roughly five weeks, its effects on appetite, fullness and digestion fade. Hunger may become more noticeable. Weight regain is common, and improvements in measures such as blood pressure and blood lipids may move back toward baseline. That pattern reflects the biology of chronic weight regulation, not a failure of character.

Stopping does not guarantee that every pound returns, and it does not produce the same result for everyone. The clearest evidence comes from randomized withdrawal trials, which report group averages rather than individual forecasts.

What happens when you stop taking semaglutide, week by week

Semaglutide has an elimination half-life of approximately one week, according to a randomized pharmacokinetic study published in Advances in Therapy in 2018 (Ikushima et al.). After one half-life, about half the exposure remains; after roughly five, only a small fraction remains. The detailed arithmetic belongs in our guide to how long semaglutide stays in your system.

During those first several weeks, medication-related appetite control and delayed gastric emptying do not switch off at a single moment. They become less pronounced as exposure falls. A small randomized trial found that semaglutide was associated with less hunger, fewer food cravings and 24% lower energy intake across test meals than placebo (Blundell et al., Diabetes, Obesity and Metabolism, 2017). It is therefore unsurprising that hunger or food preoccupation can return when that pharmacologic support recedes. This is an expected loss of drug effect, not evidence of addiction.

How much semaglutide weight regain did trials find?

The STEP 1 extension gives the most direct one-year answer. A subset of 327 participants was followed after semaglutide and the trial's lifestyle intervention ended. Those originally assigned semaglutide had lost 17.3% of body weight by week 68. Over the next year, they regained 11.6 percentage points—about two-thirds of that prior loss—leaving a mean net loss of 5.6% from the original baseline. Most measured cardiometabolic improvements moved back toward baseline (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

STEP 4 tested the decision earlier. After a 20-week semaglutide run-in and mean loss of 10.6%, 803 participants were randomized either to continue 2.4 mg weekly or switch to placebo, with lifestyle intervention in both groups. Across the next 48 weeks, the placebo-switch group gained 6.9%, while the continuation group lost another 7.9% (Rubino et al., JAMA, 2021). The design cannot predict one person's outcome, but it isolates a durable pattern: removing treatment changes the weight trajectory even when lifestyle support continues.

For the on-treatment curve and trial averages, see semaglutide weight-loss results. That page owns those results; the relevant point here is what changed after treatment ended.

The same pattern appears with tirzepatide

SURMOUNT-4 provides context from a different incretin medication. After participants lost a mean 20.9% during a 36-week tirzepatide lead-in, those switched to placebo gained 14.0% over the next 52 weeks. Those who continued tirzepatide lost another 5.5%. At week 88, 16.6% of the placebo group versus 89.5% of the continuation group had maintained at least 80% of the initial loss (Aronne et al., JAMA, 2024).

That is not evidence that one drug should replace the other. It is evidence that regain after withdrawal is not unique to semaglutide. Long-acting medications can help maintain a changed appetite and weight state only while their biologic effects remain present.

Why weight can return without anyone doing anything wrong

Weight loss prompts the body to defend its prior energy stores. Hunger can rise, satiety can weaken and energy expenditure can adapt. Semaglutide adds a pharmacologic counterweight by activating GLP-1 receptors and influencing appetite-related signaling. Once that support fades, the underlying pressure does not necessarily disappear.

This is why obesity is managed as a chronic, relapsing condition. Regain after stopping does not erase the work done during treatment. It shows that the treatment was carrying part of the load. The STEP 1 investigators' finding that several cardiometabolic measures trended back toward baseline strengthens the case for planning beyond the scale alone.

Is tapering better than stopping suddenly?

There is no established taper schedule proven by randomized trials to prevent weight regain after semaglutide. STEP 1 ended treatment, and STEP 4 switched participants to placebo; neither compared abrupt withdrawal with progressively lower doses. A gradual taper may be considered by a prescriber to observe appetite, side effects, glucose or weight response, but that is individualized clinical judgment—not a validated universal protocol.

The same distinction applies to maintenance dosing. Some care plans continue the established dose; others consider a lower dose or another medication. Lower-dose strategies are discussed separately in microdosing semaglutide, so they are not reproduced here. The prescriber sets the actual dose, and treatment should not be adjusted from a generic schedule online.

Whether treatment continues, tapers, switches or stops is a decision for the patient and prescribing clinician. At Promise, a licensed provider reviews every request and not everyone qualifies for a prescription.

What belongs in a stopping plan

A useful plan defines what will be monitored and what would trigger another conversation. That may include appetite, weight trend, blood pressure and relevant laboratory markers. For someone using semaglutide for type 2 diabetes, glucose management needs its own plan; STEP 1 and STEP 4 enrolled people without diabetes, so their withdrawal results cannot be treated as a glucose forecast.

It also helps to decide in advance what degree of regain is meaningful. Waiting for all prior weight to return turns a manageable trend into an all-or-nothing judgment. A prescriber can instead interpret the pattern alongside tolerability, treatment goals, medical history and access. The options may include continued maintenance, a clinician-directed taper, a switch, or remaining off medication with follow-up. No single choice fits every patient, but the evidence argues for making it deliberately rather than assuming the medication's effects will persist after it clears.